Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mohammad Ashraf Chaudhary, Elamin H Elbasha, Ritesh N Kumar & Esther C Nathanson. (2011) Cost–effectiveness of raltegravir in HIV/AIDS. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 627-639.
Read now
Read now
Mona Arab-Alameddine, Laurent Arhtur Décosterd, Thierry Buclin, Amalio Telenti & Chantal Csajka. (2011) Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 609-622.
Read now
Read now
Articles from other publishers (34)
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Anabela Almeida, Cristina De Mello-Sampayo, Ana Lopes, Rita Carvalho da Silva, Paula Viana & Leonor Meisel. (2023) Predicted Environmental Risk Assessment of Antimicrobials with Increased Consumption in Portugal during the COVID-19 Pandemic; The Groundwork for the Forthcoming Water Quality Survey. Antibiotics 12:4, pages 652.
Crossref
Crossref
Rohan Gurjar, Laura Dickinson, Daniel Carr, Wolfgang Stöhr, Stefano Bonora, Andrew Owen, Antonio D’Avolio, Adam Cursley, Nathalie De Castro, Gerd Fätkenheuer, Linos Vandekerckhove, Giovanni Di Perri, Anton Pozniak, Christine Schwimmer, François Raffi & Marta Boffito. (2022) Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. The Pharmacogenomics Journal 23:1, pages 14-20.
Crossref
Crossref
Jing Yang, Guo Wei, Fuqiang Gui, Yong Zhao, Tingyu Chen & Juan Tan. (2022) Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer. AIDS Research and Therapy 19:1.
Crossref
Crossref
Caroline Sychterz, Aleksandra Galetin & Kunal S. Taskar. (2021) When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations. Biopharmaceutics & Drug Disposition 42:4, pages 160-177.
Crossref
Crossref
Yi Zheng, Gabrielle Lui, Sana Boujaafar, Radia Aboura, Naïm Bouazza, Frantz Foissac, Jean-Marc Treluyer, Sihem Benaboud, Déborah Hirt & Inès Gana. (2021) Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 196, pages 113923.
Crossref
Crossref
Julian C. Gilmore, Lena Serghides & Reina Bendayan. (2021) Differential effects of antiretroviral drug toxicity in male versus female children who are HIV-exposed but uninfected. AIDS 35:1, pages 1-14.
Crossref
Crossref
Fernanda de Lima Moreira, Maria Paula Marques, Geraldo Duarte & Vera Lucia Lanchote. (2020) Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC–MS/MS with application in a maternal-fetal pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 177, pages 112838.
Crossref
Crossref
Yu-Chan Chang, Jean Chiou, Yi-Fang Yang, Chia-Yi Su, Yuan-Feng Lin, Chia-Ning Yang, Pei-Jung Lu, Ming-Shyan Huang, Chih-Jen Yang & Michael Hsiao. (2019) Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival. Cancer Research 79:18, pages 4754-4766.
Crossref
Crossref
Leïla Belkhir, Carole Seguin-Devaux, Laure Elens, Caroline Pauly, Nicolas Gengler, Serge Schneider, Jean Ruelle, Vincent Haufroid & Bernard Vandercam. (2018) Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Scientific Reports 8:1.
Crossref
Crossref
A Cozzi‐Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich, R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren & A Mocroft. (2017) Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens. HIV Medicine 19:2, pages 102-117.
Crossref
Crossref
Cécile Vinot, Jean-Marc Tréluyer, Carole Giraud, Laurent Gavard, Gilles Peytavin & Laurent Mandelbrot. (2016)
Bidirectional Transfer of Raltegravir in an
Ex Vivo
Human Cotyledon Perfusion Model
. Antimicrobial Agents and Chemotherapy 60:5, pages 3112-3114.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
687
736
.
Anne-Marie Taburet, H?l?ne Sauvageon, Beatriz Grinsztejn, Alex Assuied, Valdilea Veloso, Jos? Henrique Pilotto, Nathalie De Castro, Carine Grondin, Catherine Fagard & Jean-Michel Molina. (2015) Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clinical Infectious Diseases 61:8, pages 1328-1335.
Crossref
Crossref
Diana F. Clarke, Edward P. Acosta, Matthew L. Rizk, Yvonne J. Bryson, Stephen A. Spector, Lynne M. Mofenson, Edward Handelsman, Hedy Teppler, Carolee Welebob, Deborah Persaud, Mae P. Cababasay, JiaJia Wang & Mark Mirochnick. (2014) Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:3, pages 310-315.
Crossref
Crossref
Francesca Esposito & Enzo Tramontano. (2014) Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors. Antiviral Chemistry and Chemotherapy 23:4, pages 129-144.
Crossref
Crossref
Thammarse S. Yamuna, Jerry P. Jasinski, Brian J. Anderson, H. S. Yathirajan & Manpreet Kaur. (2013) Raltegravir monohydrate. Acta Crystallographica Section E Structure Reports Online 69:12, pages o1743-o1744.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Diana F. Clarke, Ronald J. Wong, Larissa Wenning, David K. Stevenson & Mark Mirochnick. (2013) Raltegravir In Vitro Effect on Bilirubin Binding. Pediatric Infectious Disease Journal 32:9, pages 978-980.
Crossref
Crossref
Ruxandra Calin & Christine Katlama. (2013) The place of raltegravir in the clinical management of HIV-1 infection. Clinical Practice 10:4, pages 427-438.
Crossref
Crossref
Clara T. M. M. de Kanter, Maren I. Blonk, Angela P. H. Colbers, Bas J. J. W. Schouwenberg & David M. Burger. (2013) Lack of a Clinically Significant Drug?Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. Clinical Infectious Diseases 56:2, pages 300-306.
Crossref
Crossref
Ruxandra Calin, Luc Paris, Anne Simon, Gilles Peytavin, Marc Wirden, Luminita Schneider, Marc-Antoine Valantin, Roland Tubiana, Rachid Agher & Christine Katlama. (2012) Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy. Antiviral Therapy 17:8, pages 1601-1604.
Crossref
Crossref
Maren Blonk, Angela Colbers, Anne Poirters, Bas Schouwenberg & David Burger. (2012) Effect of Ginkgo Biloba on the Pharmacokinetics of Raltegravir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 56:10, pages 5070-5075.
Crossref
Crossref
Erik M. van MaarseveenChristin C. RogersJennifer Trofe-ClarkArjan D. van ZuilenTania Mudrikova. (2012) Drug–Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review. AIDS Patient Care and STDs 26:10, pages 568-581.
Crossref
Crossref
Ighovwerha OfotokunAnandi N. ShethSara E. SanfordKirk A. EasleyNeeta ShenviKelly WhiteMolly E. EatonCarlos Del RioJeffrey L. Lennox. (2012) A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. AIDS Research and Human Retroviruses 28:10, pages 1196-1206.
Crossref
Crossref
Jonas Demeulemeester, Cristina Tintori, Maurizio Botta, Zeger Debyser & Frauke Christ. (2012) Development of an AlphaScreen-Based HIV-1 Integrase Dimerization Assay for Discovery of Novel Allosteric Inhibitors. SLAS Discovery 17:5, pages 618-628.
Crossref
Crossref
Mona Arab-Alameddine, Aurélie Fayet-Mello, Rubin Lubomirov, Michael Neely, Julia di Iulio, Andrew Owen, Marta Boffito, Matthias Cavassini, Huldrych F. Günthard, Katharina Rentsch, Thierry Buclin, Manel Aouri, Amalio Telenti, Laurent Arthur Decosterd, Margalida Rotger & Chantal Csajka. (2012) Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy 56:6, pages 2959-2966.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Cristina Tintori, Jonas Demeulemeester, Luigi Franchi, Silvio Massa, Zeger Debyser, Frauke Christ & Maurizio Botta. (2012) Discovery of small molecule HIV-1 integrase dimerization inhibitors. Bioorganic & Medicinal Chemistry Letters 22:9, pages 3109-3114.
Crossref
Crossref
Akil Jackson, Graeme Moyle, Laura Dickinson, David Back, Saye Khoo, Jessica Taylor, Keerti Gedela, George Abongomera, Brian Gazzard & Marta Boffito. (2012) Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy 17:1, pages 19-24.
Crossref
Crossref
Natella Y. Rakhmanina & Charles J.L. la Porte. 2012. Therapeutic Drug Monitoring. Therapeutic Drug Monitoring
373
396
.
Lingzhi Wang, Gaik Hong Soon, Kok-Yong Seng, Jun Li, Edmund Lee, Eu-Leong Yong, Boon-Cher Goh, Charles Flexner & Lawrence Lee. (2011) Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 55:9, pages 4090-4095.
Crossref
Crossref
J. Ashby, L. Garvey, O. W. Erlwein, H. Lamba, R. Weston, K. Legg, N. Latch, M. O. McClure, L. Dickinson, A. D'Avolio, D. Back & A. Winston. (2011) Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. Journal of Antimicrobial Chemotherapy 66:6, pages 1340-1345.
Crossref
Crossref
A. Jackson, A. D'Avolio, V. Watson, S. Bonora, D. Back, J. Taylor, K. Armenis, B. Gazzard, G. Moyle & M. Boffito. (2011) Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. Journal of Antimicrobial Chemotherapy 66:4, pages 885-889.
Crossref
Crossref